{"type":"rich","version":"1.0","title":"BioPharm Brief: Dermatology, Neurology, and Oncology Updates","description":"This week's BioPharm Brief covers the FDA's approval of every-eight-week maintenance dosing for lebrikizumab in atopic dermatitis, Sanofi's decision to halt a Phase 3 CIDP study of riliprubart after a futility analysis, and new mogamulizumab data being presented at WCCL 2026 in cutaneous T-cell lymphoma.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43692023/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":"<iframe width=\"100%\" height=\"95\" src=\"https://embeds.audioboom.com/posts/8915183/embed?v=202301\" style=\"background-color: transparent; display: block; padding: 0; width: 100%\" frameborder=\"0\" allowtransparency=\"allowtransparency\" scrolling=\"no\" title=\"Audioboom player\" allow=\"autoplay\" sandbox=\"allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation\"></iframe>"}